China healthcare sector Report Interpretation

Overview

This China Healthcare Pulse reviews 2Q/1H26 earnings across the sector. Goldman Sachs finds that the healthcare recovery is becoming more durable, led by CRO/CDMOs and increasingly supported by biotech innovation, global expansion and selected domestic-demand inflections, though recovery remains uneven across subsectors.

Core views

Goldman Sachs says its early-July window for a derisked re-entry into China healthcare has played out, with CRO/CDMOs the clearest winners. The firms cited broad earnings beats, FY26 guidance upgrades and exceptionally strong orders, as well as a rise in generalist investor interest. WuXi AppTec, WuXi Biologics, WuXi XDC, Pharmaron and GenScript raised FY26 outlooks, while reported backlog or order growth included WuXi AppTec +25%, WuXi Biologics +24%, WuXi XDC +50%, Asymchem +54% and Pharmaron +30%. The institution sees improving utilization, operating leverage and rising exposure to higher-value modalities as supporting consensus upgrades into 2027. The recovery is broadening beyond GLP-1-led commercial manufacturing. WuXi AppTec reported a sharp rebound in preclinical and Phase I molecule additions; WuXi Biologics added a record 169 integrated projects; WuXi XDC signed a record 51; and Pharmaron's clinical-development order intake rose 30%. Goldman Sachs interprets this as early-stage R&D recovery, reinforced by stabilizing biotech funding, active licensing and M&A activity, and global innovation demand. Increased investment in peptides, ADCs, oligonucleotides, biologics and overseas capacity, alongside growing AI-driven drug discovery demand, strengthens its view that both near-term execution and longer-term innovation are supporting the sector. For biotech and pharma, the report sees financials improving through resilient innovative-drug sales, business-development income, operating leverage and cost discipline. Innovent, Kelun Biotech, InnoCare and Keymed were cited for strong product sales and clinical differentiation; Innovent had US$4.5bn of cash and equivalents at end-July. Goldman Sachs argues that anti-corruption tightening created temporary commercial disruption rather than structural demand destruction: activity improved sequentially through July and August, while differentiated products continued to grow. By contrast, mature products, generics and selected biosimilars faced pressure from pricing, competition or lifecycle maturity. Sino Biopharm reported +63% year-on-year core-profit growth and Hansoh +19% profit growth excluding investment gains, illustrating operating leverage. The report argues that the China-to-global investment case is becoming more concrete. It highlights global registrational plans and clinical readouts, including Innovent's aim for more than five programs to reach Phase III multi-regional clinical trials by 2030; Kelun Biotech's expected first global Phase III sac-TMT readouts within 12 months; Ascletis' two global Phase III obesity studies involving about 4,600 patients; and CStone's planned FDA consultation in 4Q26 and registrational-trial start by year-end. Near-term catalysts are WCLC in September and ESMO in October, particularly for TROP2, DLL3 and B7-H3 ADCs, PD-1/VEGF and RAS-targeted therapies. The report notes stronger interest in mRNA cancer vaccines and RAS therapies but more caution on PD-1/VEGF after the HARMONi-6 PFS hazard ratio changed from 0.6 to 0.72. In MedTech and services, Goldman Sachs sees gradual domestic recovery rather than a broad demand rebound. Hospital bidding turned positive year-on-year in June and July, supported by trade-in funding and replacement demand for Covid-era equipment. United Imaging reported more than 50% overseas revenue growth, while Mindray sustained about 10% overseas growth despite adverse currency translation. In IVD, the staggered rollout of reagent volume-based procurement, normalization of distributor inventory and leading domestic firms' market-share gains created an initial 2Q26 inflection; leading Chinese IVD firms still hold less than 5% of international markets, leaving substantial overseas growth potential. Globalization is the principal differentiator in MedTech and services. Angelalign raised FY26 total case-volume guidance to 700,000, up 32% year-on-year, including 350,000 overseas cases, up 37%; overseas revenue grew 65% in 1H26 and profitability arrived ahead of schedule. AK Medical's overseas revenue rose 42%, versus +3% domestically, lifting gross margin by 4.6 percentage points. Edge Medical placed or delivered 49 of 58 systems overseas in 1H26, with overseas revenue nearing 70% of sales. The report also notes increasing shareholder distributions, including Angelalign's HK$4.57 per-share dividend, Gushengtang's commitment to at least HK$450mn annual distributions and a HK$300mn buyback, and Hygeia's roughly Rmb500mn annual buyback-and-dividend plan for 2026-28. Elsewhere, retail pharmacy reached an inflection in 1H26: operating-store count turned positive year-on-year, expanded month-on-month for five consecutive months through July, and average revenue per store had risen year-on-year since May 2025. Goldman Sachs expects leading chains to outperform through innovative-drug demand, non-pharmaceutical categories and consolidation. In contrast, it remains cautious on plasma because volume-based procurement, DRG/DIP reforms and continued collection-volume expansion are pressuring demand, prices and margins. Vaccines remain in a trough due to lower ASPs, weak birth rates, hesitancy and competition, while insulin faces VAT-related ASP pressure but retains domestic-substitution and overseas opportunities. Valuation and positioning have recovered quickly from June lows. China onshore healthcare traded at 21.5x aggregate 12-month forward P/E as of September 7, while onshore and offshore healthcare traded at 2.0x and 1.6x P/S, respectively. Goldman Sachs characterizes valuation multiples as in the medium range and notes strong recent trading interest in CRO/CDMO. Its sector preference is CDMO first, selective pharma/biotech second, with a more guarded stance on medical consumables, services and plasma.

Analysis framework

Goldman Sachs combines 2Q/1H26 company results and guidance with order and backlog trends, funding and licensing activity, clinical catalysts, procurement and bidding data, cross-sector operating evidence, trading activity and aggregate valuation comparisons. It evaluates which earnings changes are cyclical, which are structural, and which companies or segments have stronger exposure to global growth and innovation.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  Aggregate 12-month forward P/E, P/S and peer PE/PEG comparisons

  The report compares sector and company valuation using market capitalization divided by aggregate 12-month forward consensus estimates, plus peer growth and valuation comparisons.

• Industry AnalysisSupply-demand framework

  Subsector supply-demand assessment

  The report links orders, capacity investment, procurement, replacement demand, pricing, funding and policy to earnings and industry outlooks across healthcare segments.

• Event-Driven and Behavioral FinanceEvent-driven analysis

  Clinical, conference and regulatory catalyst tracking

  It identifies WCLC, ESMO, clinical readouts, approvals and global-trial milestones as events that may affect confidence in innovation and commercialization.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec, WuXi XDC, Pharmaron, Asymchem, Tigermed

  Preferred CRO/CDMO exposure to order recovery and broadening R&D demand

  Strengths

  Earnings beats, guidance upgrades, backlog growth and operating leverage.

  Weaknesses

  FX headwinds and reliance on continued project conversion.

  Comparison

  Goldman Sachs views CRO/CDMO as the preferred healthcare segment.

  Risks

  Geopolitical headlines, profit-taking and a weaker funding or order environment.

• BeOne, Innovent, Kelun Biotech, Keymed, GenFleet, Hansoh

  Preferred selective biotech and pharma names

  Strengths

  Clinical differentiation, profitability improvement, business-development income and global pipeline execution.

  Weaknesses

  Several value cases depend on data readouts and global registration progress.

  Comparison

  Preferred over less differentiated, mature or price-pressured products.

  Risks

  Clinical, regulatory, commercialization and competition risks.

• Mindray, United Imaging, Angelalign, Edge Medical

  Preferred MedTech exposure to domestic normalization and global expansion

  Strengths

  Overseas execution, equipment replacement demand and improving procurement trends.

  Weaknesses

  Domestic recovery remains gradual and uneven.

  Comparison

  Globalization differentiates these companies from China-demand-dependent peers.

  Risks

  Hospital-budget constraints, procurement disruption, VBP and currency effects.

Key data

• CRO/CDMO order or backlog growthWuXi AppTec +25%; WuXi Biologics +24%; WuXi XDC +50%; Asymchem +54%; Pharmaron +30%Reported sector momentum supporting medium-term growth visibility.
• WuXi Biologics integrated projects169Record additions, cited as evidence of recovering earlier-stage activity.
• WuXi XDC integrated projects51Record signed projects.
• Innovent cash and equivalentsUS$4.5bnAt end-July; cited as supporting pipeline investment and global expansion.
• Angelalign FY26 case-volume guidance700,000 total cases; 350,000 overseas casesUp 32% and 37% year-on-year, respectively.
• China onshore healthcare valuation21.5x 12-month forward aggregate P/EAs of September 7, 2026.
• China biotech deal valueMore than US$100bnTotal out-licensing business-development and acquisition deal value in 1H26.

Impact & implications

Goldman Sachs sees a shift from a narrow commercial-manufacturing rebound to a broader healthcare re-rating driven by early-stage R&D, global clinical execution, overseas commercialization and selective domestic-demand recovery. It considers CDMOs best positioned, favors selective innovators and internationally expanding MedTech companies, and distinguishes them from segments still constrained by policy, pricing or oversupply.

Risks

• Biotech funding momentum slowed modestly overseas while domestic funding remained muted.
• Geopolitical headlines and shareholder-disposal concerns may cause periodic profit-taking.
• Domestic healthcare recovery remains uneven amid pricing pressure, hospital-budget constraints and procurement disruptions.
• Plasma faces oversupply, falling prices and utilization pressure from VBP and DRG/DIP reforms.
• Vaccine demand remains constrained by VAT-related ASP pressure, low birth rates, hesitancy and competition.

What to watch

• CRO/CDMO order intake, backlog conversion, guidance revisions and early-stage R&D demand.
• WCLC and ESMO data for ADCs, PD-1/VEGF and RAS-targeted therapies.
• Global Phase III initiation, clinical data and regulatory milestones for China biotech assets.
• Hospital-equipment bidding, trade-in funding utilization and MedTech channel inventories.
• Overseas revenue execution and shareholder-return delivery across MedTech and healthcare-services companies.